Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

To explore early effects of GH treatment or deprivation on cardiovascular risk factors and carotid intima-media thickness (IMT), the researchers designed this randomized, cross-over study in 34 adult patients with severe GH deficiency.

Who Took Part

The abstract describes 34 patients taking part.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized and crossover.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

What Was Measured

The subject headings attached to it are C-Reactive Protein, Carotid Arteries, Cholesterol, HDL, Growth Hormone, Hormone Replacement Therapy, Human Growth Hormone and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 34 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2005 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.